Abeona Therapeutics (NASDAQ:ABEO) Posts Earnings Results, Beats Estimates By $0.09 EPS

Abeona Therapeutics (NASDAQ:ABEO) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09, FiscalAI reports. Abeona Therapeutics had a negative net margin of 160.30% and a negative return on equity of 43.40%. The company had revenue of $13.49 million during the quarter, compared to the consensus estimate of $14.82 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN revenue rose 18% sequentially to $13.5 million, with six patients treated during the quarter and 15 treated since launch. The network expanded to eight qualified treatment centers, four of which have treated patients.
• Patient treatment timing remains variable as patients and centers work through authorization, scheduling, and other steps; a planned manufacturing shutdown from mid-November to mid-January is expected to shift some treatments into 2027. The company reported one out-of-specification batch among 15 treated patients and is not providing patient-funnel numbers.
• Abeona acquired ABO-801, a phase III-stage EoE candidate, for $20 million in stock, with additional approval and commercial milestone payments and tiered royalties owed to Ellodi. Management sees potential for peak annual revenue above $750 million and plans a roughly 400-patient phase III trial, pending FDA feedback, with initiation expected in mid-2027.
• ABO-801 showed histologic and endoscopic activity in prior trials, but neither study individually met its co-primary symptom endpoint; management attributes this in part to the symptom-assessment tool and plans to use the DSQ in the next trial. The company estimates $50 million–$60 million to develop the drug through approval and says its cash, private-placement proceeds, expected ZEVASKYN sales, and FAYUVI royalties provide funding support.

Abeona Therapeutics Stock Down 3.5%

Shares of NASDAQ ABEO opened at $2.45 on Wednesday. The stock has a market cap of $140.10 million, a PE ratio of -2.29 and a beta of 1.50. The business has a fifty day moving average of $4.92 and a two-hundred day moving average of $5.43. Abeona Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.40 and a current ratio of 6.63.

Key Headlines Impacting Abeona Therapeutics

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: Abeona acquired ABO-801, a Phase 3-ready oral candidate for eosinophilic esophagitis with FDA Fast Track and Orphan Drug designations. The deal expands the pipeline, though development will require further investment. Abeona acquisition and private placement
• Positive Sentiment: Q3 ZEVASKYN revenue reached $13.5 million, up 18% sequentially. The company reported 15 treatments completed since launch, expanded its treatment network to eight sites, and had $134.9 million in cash and short-term investments at quarter-end. Q3 results and commercial update
• Neutral Sentiment: Management plans to participate in November investor conferences, but no new clinical or commercial data were announced with the notice. Investor conference announcement
• Negative Sentiment: The company agreed to a $30 million private placement to support its plans. The financing may raise dilution concerns for existing shareholders. Also, Q3 revenue of $13.49 million fell short of the $14.82 million analyst consensus, despite EPS beating estimates. Financing announcement

Insider Buying and Selling

In other news, CEO Vishwas Seshadri sold 19,608 shares of the company’s stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total value of $101,177.28. Following the sale, the chief executive officer owned 1,286,500 shares of the company’s stock, valued at approximately $6,638,340. This represents a 1.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Joseph Vazzano sold 9,191 shares of the company’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $47,425.56. Following the completion of the sale, the chief financial officer directly owned 482,888 shares in the company, valued at approximately $2,491,702.08. The trade was a 1.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 55,428 shares of company stock worth $296,508 in the last three months. Company insiders own 7.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ABEO. HC Wainwright reissued a “buy” rating on shares of Abeona Therapeutics in a research note on Friday, September 25th. Cantor Fitzgerald raised their price target on shares of Abeona Therapeutics from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, September 18th. UBS Group reaffirmed a “buy” rating on shares of Abeona Therapeutics in a report on Friday, September 25th. Wall Street Zen raised Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Finally, Roth Capital began coverage on Abeona Therapeutics in a research note on Thursday, September 17th. They issued a “buy” rating and a $17.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Abeona Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $21.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc. (NASDAQ: ABEO) is a biopharmaceutical company focused on developing and commercializing cell and gene therapies for serious and rare genetic diseases. The company’s programs are designed to address conditions with limited treatment options, including diseases caused by genetic defects affecting the skin and other tissues. Abeona’s lead product, prademagene zamikeracel, is an autologous cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare inherited disorder that causes fragile skin and chronic wounds.